Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Wednesday that it has submitted a New Drug Application (NDA) to the United States (US) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara, 18F-floretyrosine or 18F-FET), an investigational positron emission tomography (PET) agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and paediatric patients.
The product has received Orphan Drug and Fast Track designation from the FDA to facilitate accelerated review and closer consultation with the agency during the review process. It is already included in international clinical practice guidelines for the imaging of gliomas, but there is presently no FDA-approved targeted amino acid PET agent for adult and paediatric brain cancer imaging commercially available in the United States.
Kevin Richardson, Telix Precision Medicine chief executive officer, said: "Gliomas are the most common primary brain tumours of the central nervous system. Conventional imaging with MRI often yields inconclusive results in characterising recurrent disease and therefore delays time-sensitive decision making. Limitations of conventional imaging techniques include the lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumour progression or treatment-related causes. Telix's filing of this NDA for Pixclara is an important milestone, reflecting our commitment to improved and accessible neuro-oncology imaging in the US, and taking us one step closer to commercial availability in 2025, subject to FDA approval."
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities
Newron and EA Pharma sign licensing deal for Evenamide in Asia
Cybin selects Facet Life Sciences as US regulatory partner
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Merck's WELIREG approved in China for VHL disease
AbbVie signs new discovery, co-development and licence agreement with Gedeon Richter
JCR Pharmaceuticals showcases preclinical gene therapy advances at ESGCT Congress
Revalesio reveals new RNS60 related data
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Charles River and Lundbeck partner to advance neurological drug discovery using AI-powered Logica
Vesper Bio announces positive Phase I results for FTD treatment